868963-98-8

Basic information

• Product Name: 2-Amino-5-bromopyridine-3-sulfonyl chloride
• Synonyms: 2-Amino-5-bromopyridine-3-sulfonyl chloride;2-amino-5-bromo-3-pyridinesulfonyl chloride;3-Pyridinesulfonyl chloride, 2-aMino-5-broMo-
• CAS NO: 868963-98-8
• Molecular Formula: C₅H₄BrClN₂O₂S
• Molecular Weight: 271.52
• Mol File: 868963-98-8.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 284.2 °C at 760 mmHg
• Flash Point: 125.7 °C
• Appearance: /
• Density: 1.970
• PKA: -0.76±0.49(Predicted)
• CAS DataBase Reference: 2-Amino-5-bromopyridine-3-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-bromopyridine-3-sulfonyl chloride(868963-98-8)
• EPA Substance Registry System: 2-Amino-5-bromopyridine-3-sulfonyl chloride(868963-98-8)

Safety Data

• Hazardous Substances Data: 868963-98-8(Hazardous Substances Data)

Usage

General Description

2-Amino-5-bromopyridine-3-sulfonyl chloride is a chemical compound with the molecular formula C5H5BrN2O2SCl. It is a sulfonyl chloride derivative of pyridine that contains an amino group and a bromine atom. 2-Amino-5-bromopyridine-3-sulfonyl chloride is commonly used in the pharmaceutical industry as a building block in the synthesis of various pharmaceutical agents and biologically active molecules. It is known for its role in the production of antiviral, antibacterial, and anticancer drugs. Additionally, it is used as a reagent in organic synthesis and chemical research due to its ability to form various chemical bonds and functional groups. Its unique chemical structure and versatile reactivity make it an important molecule in the field of medicinal chemistry and drug discovery.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 7790-94-5 chlorosulfonic acid 

Downstream Products

• 1083326-15-1 2-amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide 
• 1272355-01-7 2-methyl-6-(5-phenyl-4-(pyridine-2-ylmethylamino)quinazolin-2-yl)imidazo[1,2-a]pyridine-8-sulfonamide 
• 1298029-82-9 [2-(4-bromo-2-fluorobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-83-0 [2-(3-nitrobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-84-1 [2-(4-(trifluoromethyl)benzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-85-2 [2-(2,4,5-trifluorobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-86-3 [2-(4-methoxybenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-97-6 [2-(4-bromo-2-fluorobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298029-98-7 [2-(3-nitrobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298029-99-8 [2-(4-(trifluoromethyl)benzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-00-8 [2-(2,4,5-trifluorobenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-06-4 [2-(4-methoxybenzyl)-7-bromo-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 869008-40-2 2-amino-5-bromo-N-(2,4-difluorophenyl)pyridine-3-sulphonamide 
• 1366132-02-6 2-amino-5-{2-amino-1-[4-(4-morpholinyl)phenyl]-1H-benzimidazol-6-yl}-N-(2,4-difluorophenyl)-3-pyridinesulfonamide 

Relevant articles and documents

Pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors

The present invention discloses a class of pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors, and particularly relates to a compound represented by a formula (I) or a pharmaceutically acceptable salt thereof. The formula (I) is defined in the specification.

PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF

Compounds of formula (la) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, -C1-Cealkyl, -C1-Ceaminoalkyl, -C1-C6hydroxyalkyl, -haloC1-C6alkyl, -C1- C6alkoxyl, -haloC1-C6alkyl, -CH2OC(O)CrC6alkyl, -C(O)OC1,-C6alkyI, -NHC(O)C1,-C6alkyl, -NHS(O)2C1- C6alkyl, -S(O)2C1-C6alkyl, -S(O)2NH2, and -C(O)NJJ; Ring B is a 6-10 membered arylene or a 5-6 membered heteroarylene comprising at least one heteroatom selected from N, 0 or S; and wherein the aryl or heteroaryl is optionally, substituted with one or more substituents selected from -NJJ, -OJ, halo,C1 -C6alkyl, -haloC1- C6alkyl, -C1-C6alkoxy, -haloC1-C6alkoxyl, and -C(0)NJJ; Ring C is is selected from a 5-10 membered heteroarylene or a 5-10 membered heterocyclene, each comprising at least one heteroatom selected from N, S and O; Ring D is an optionally substituted benzofused 9-11 membered heterocyclyl or optionally substituted ben2ofused 9-11 membered heteroaryl comprising at least one heteroatom selected from N or O; L is a linker selected from branched and unbranched C1-C4 alkylene, -S(0)2-NH-, -C(0)-NH-, -NH-C(0)-NH-, -S(0)2-NH-C(0)-NH-, -S(0)2-NH-C(0) - and -CH=CH-; wherein Rings B and C, and Rings C and D, are connected to each other via a C-C bond at any of the available C atoms on each respective ring; and J in each occurrence is independently selected from H, optionally substituted C1-C6alkyl or optionally substituted haloC1-C6alkyl.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors

The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease. A large body of evidence has linked PI3Kγ to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery. Our high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies. The in vitro activity of the first HTS hit, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design. However, nonoptimal pharmacokinetic properties precluded this series from further studies. An overlay of the X-ray structures of the sulfonylpiperazine scaffold and the second HTS hit within their complexes with PI3Kγ revealed a high degree of overlap. This feature was utilized to design a series of hybrid analogues including advanced leads such as 31 with desirable potency, selectivity, and oral bioavailability.